Bacteria: a new player in gastrointestinal motility disorders--infections, bacterial overgrowth, and probiotics.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Quigley, Eamonn M MAffiliation
Department of Medicine, Alimentary Pharmabiotic Centre, University College Cork, , Clinical Sciences Building, Cork University Hospital, Cork, Ireland., e.quigley@ucc.ieIssue Date
2012-02-03T15:16:22ZMeSH
Bacteria/*growth & development*Bacterial Infections/complications/drug therapy/microbiology
*Gastrointestinal Diseases/drug therapy/etiology/microbiology
Gastrointestinal Tract/*microbiology
Humans
Probiotics/*therapeutic use
Metadata
Show full item recordCitation
Gastroenterol Clin North Am. 2007 Sep;36(3):735-48, xi.Journal
Gastroenterology clinics of North AmericaDOI
10.1016/j.gtc.2007.07.012PubMed ID
17950446Abstract
Irritable bowel syndrome (IBS) may result from a dysfunctional interaction between the indigenous flora and the intestinal mucosa, which in turn leads to immune activation in the colonic mucosa. Some propose that bacterial overgrowth is a common causative factor in the pathogenesis of symptoms in IBS; others point to evidence suggesting that the cause stems from more subtle qualitative changes in the colonic flora. Bacterial overgrowth will probably prove not to be a major factor in what will eventually be defined as IBS. Nevertheless, short-term therapy with either antibiotics or probiotics seems to reduce symptoms among IBS patients. However, in the long term, safety issues will favor the probiotic approach; results of long-term studies with these agents are eagerly awaited.Language
engISSN
0889-8553 (Print)0889-8553 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1016/j.gtc.2007.07.012